Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

Could the Silver Price Really Hit US$100 per Ounce? (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Top 10 Copper-producing Companies (Updated 2024)

Top 10 Countries for Natural Gas Production (Updated 2024)

7 Biggest Lithium-mining Companies

11 Canadian Cryptocurrency ETFs (Updated 2024)

Where Does Tesla Get its Lithium? (Updated 2024)

Top 7 Canadian Lithium Stocks of 2024

Hydrogen Stocks: 9 Biggest Companies

Trending Press Releases

Galan Lithium Limited (ASX: GLN) – Trading Halt

Edison Lithium Expands Portfolio with Acquisition of Additional Sodium Brine Claim in Saskatchewan

Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Bitcoin Well Launches Cash Vouchers For Canadian Customers

Osisko Metals Reports Preliminary Metallurgical Testwork Results From Gaspé Copper

Steppe Gold Enters Into Share Exchange Agreement to Acquire Boroo Gold and Agrees to Sell the Tres Cruces Oxide Project

More Press Releases
Trending Companies

Ramp Metals

RAMP:CC

Purpose Bitcoin ETF

BTCC:CA

Galan Lithium

GLN:AU

Trident Royalties PLC

TDTRF
More Companies
Trending Reports

2024 EV Market Outlook Report

2024 Lithium Market Outlook

2024 Uranium Outlook (Updated for Q2)

2024 Life Science Outlook Report

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold
Copper
Uranium
Oil and Gas
Artificial Intelligence
Biotech
loader

Cellectar Biosciences Inc.

NASDAQ:CLRB
Press Releases

Cellectar Granted Japanese Patent for CLR 131

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

×